14 December 2009
Acacia Pharma Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)
Cambridge, UK – 14th December 2009: Acacia Pharma announces the completion of its Phase II study of APD405 in the prevention of post-operative nausea & vomiting (PONV). The study was initiated in June 2009 and randomised 257 evaluable surgical patients. The data indicated that APD405 offered no significant improvement over placebo in the prevention of PONV. The project has been terminated.